The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer

Their antiangiogenic effects make vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors useful for cancer treatment. However, most of these drugs have unexpected adverse side effects. Here, we show that the novel VEGFR2 inhibitor YLL545 suppressed tumor angiogenesis and growth in triple-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jianbo, Liu, Chen, Shi, Wen, Yang, Lingling, Zhang, Quansheng, Cui, Jianlin, Fang, Yangwu, Li, Yuhao, Ren, Guosheng, Yang, Shuang, Xiang, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173043/
https://www.ncbi.nlm.nih.gov/pubmed/27203384
http://dx.doi.org/10.18632/oncotarget.9392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173043/
https://www.ncbi.nlm.nih.gov/pubmed/27203384
http://dx.doi.org/10.18632/oncotarget.9392

Ejemplares similares